Drug Discovery

Pfizer and Arvinas to jointly develop and commercialise breast cancer drug

Pfizer and Arvinas have collaborated to co-develop and co-commercialise ARV-471, an investigational oral Protac estrogen receptor protein degrader.

Three US drug distributors agree to pay $1.18bn to settle opioid case in New York

McKesson Corporation, Cardinal Health and Amerisource Bergen Drug, the three largest US drug distributors, have agreed to pay up to $1.18bn to settle the ongoing opioid-related case with the New York State and its participating subdivisions Nassau County and Suffolk County.

Partners Group to acquire Pharmathen from BC Partners for $1.9bn

Private equity firm Partners Group has agreed to acquire Pharmathen from an international investment firm BC Partners in a deal valued about $1.88bn (€1.6bn).

GSK to build new biotech and life sciences campus in Stevenage

GlaxoSmithKline (GSK) has announced plans to construct a new campus for biotechnology and early-stage life science companies in Stevenage, England.

Regeneron plans $1.8bn investment to expand research facilities in New York, US

Regeneron has announced plans to invest about $1.8bn to expand its facilities at its Westchester County campus in the US, over the next six years.

Novo Nordisk to acquire Prothena’s ATTR amyloidosis programme for $1.2bn

Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn.

Altesa signs license agreement with Vaxart for Vapendavir antiviral

Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.

Eureka and MSK sign license agreement with Sanofi for GPRC5D binder

Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) have signed a new G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) license agreement with Sanofi to target multiple myeloma.

GSK, Alector to co-develop antibodies for neurodegenerative diseases

GlaxoSmithKline (GSK) and Alector have partnered to co-develop and commercialise two clinical stage monoclonal antibodies for neurodegenerative diseases.